Emergent BioSolutions Inc. EBS
6.05 USD -0.05 (-0.82%)
At closeNov 10, 2026, 7:03 PM EST
6.14 +0.09 +1.44%
After hours · Nov 10, 7:03 PM ET
5.82 Day range 6.13
4.45 52-week range 13.90
- YTD
- -51.05%
- 1 year
- -44.95%
News
seekingalpha.com Emergent BioSolutions: A Turnaround Still Waiting For Consistent Execution Emergent BioSolutions remains a hold as commercial recovery is uncertain despite progress on cost savings and debt reduction. EBS lowered FY26 revenue and EBITDA guidance, citing government…
benzinga.com Emergent BioSolutions Awarded $22.3M Contract Modification To Provide BioThrax To U.S. Department Of War Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply…
businesswire.com Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order…
benzinga.com Adeia Posts Downbeat Q3 Earnings, Joins Bioventus, Apple And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures mixed as Adeia plunges 23% after missing Q3 estimates and cutting FY26 guidance; Bioventus, Emergent and others also fall premarket.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Dyadic International (NASDAQ:DYAI) stock rose 13.4% to $0.43 during Tuesday's pre-market session. The market value of their outstanding shares is at $15.0 million. Aethlon Medical…
fool.com Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors Full-year revenue guidance was updated to $600 million to $645 million. Restructuring actions are expected to generate $40 million in annualized savings.
benzinga.com Why Aehr Test Systems Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket Aehr surged 15% after strong Q1 results and raised FY27 guidance; Mercer, HUB Cyber and Parabolic led gainers, while VCIG and Jaguar fell.
seekingalpha.com Emergent BioSolutions Inc. (EBS) Q3 2026 Earnings Call Transcript Emergent BioSolutions Inc. (EBS) Q3 2026 Earnings Call Transcript
marketbeat.com Emergent Biosolutions Q3 Earnings Call Highlights Emergent Biosolutions NYSE: EBS reported third-quarter revenue within its guidance range and updated its full-year outlook, while continuing a multiyear transformation focused on cost control, debt…
benzinga.com Emergent BioSolutions Q3 2026 Earnings Call Transcript Emergent BioSolutions (NYSE:EBS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Emergent BioSolutions Lowers FY2026 Sales Guidance from $645.000M-$675.000M to $600.000M-$645.000M vs $657.133M Est Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $645.000 million-$675.000 million to $600.000 million-$645.000 million vs $657.133 million estimate.
benzinga.com Emergent BioSolutions Q3 Adj. EPS $(0.36) Beats $(0.39) Estimate, Sales $110.000M Miss $123.200M Estimate Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 133.96 percent decrease over earnings…
businesswire.com Emergent Biosolutions Reports Third Quarter 2026 Financial Results GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2026. “Emergent's third-quarter results, which…
businesswire.com Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer, will retire from the…
zacks.com Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the…
benzinga.com Novavax Shorts on Edge as Russia Plague Fears Spread Unconfirmed plague fears sent Novavax up 24% in a potential short squeeze, lifting vaccine stocks despite no clear link to its products.
invezz.com Russian plague outbreak could boost these under-the-radar pharma stocks Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in…
defenseworld.net Emergent Biosolutions (NYSE:EBS) Stock: Insider Paul Anthony Williams Sells 3,000 Shares Emergent Biosolutions Inc. (NYSE: EBS - Get Free Report) SVP Paul Williams sold 3,000 shares of the company's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an…
defenseworld.net Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Consensus Price Target of $10.00 Emergent Biosolutions Inc. (NYSE: EBS - Get Free Report) has received an average recommendation of "Hold" from the six analysts that are currently covering the stock, MarketBeat reports. Two equities…
defenseworld.net Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS) Coherus Oncology (NASDAQ: CHRS - Get Free Report) and Emergent Biosolutions (NYSE: EBS - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are…
globenewswire.com Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing…
benzinga.com HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $10 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $10 price target.
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).
globenewswire.com Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its…- benzinga.com Emergent BioSolutions Receives ~$24M Contract Modification From Biomedical Advanced Research And Development Authority For Strategic Preparedness Response Within U.S. Department Of Health And Human Services To Provide CYFENDUS Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the…
benzinga.com Emergent BioSolutions Receives Canada's Offer To Provide NARCAN Nasal Spray, Effective Oct. 1 Through September 2029 Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray.…- benzinga.com World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
benzinga.com HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $12 to $10.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…- benzinga.com Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 million analyst estimate.
benzinga.com Emergent BioSolutions Lowers FY2026 Sales Guidance from $720.000M-$760.000M to $645.000M-$675.000M vs $733.050M Est Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $720.000 million-$760.000 million to $645.000 million-$675.000 million vs $733.050 million estimate.- benzinga.com Emergent BioSolutions Secures $52.7M U.S. Government Contract Modification For ACAM2000 Smallpox And Mpox Vaccine Supply Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the…
benzinga.com FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose- benzinga.com Emergent BioSolutions Wins $64.5M U.S. HHS Contract Modification To Supply Botulism Antitoxin BAT Under Existing 10-Year Agreement Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response…
- benzinga.com U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide https://www.cdc.gov/ebola/situation-summary/index.html
- benzinga.com Emergent BioSolutions Announces Saudi Approval For ACAM2000, Its Smallpox and Mpox Vaccine Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia)…
benzinga.com Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 million analyst estimate.- benzinga.com Emergent BioSolutions Affirms FY2026 Sales Guidance of $720.000M-$760.000M vs $735.000M Est Emergent BioSolutions (NYSE:EBS) affirms FY2026 sales outlook from $720.000 million-$760.000 million to $720.000 million-$760.000 million vs $735.000 million estimate.
- benzinga.com Emergent BioSolutions Q1 Adj. EPS $0.21 Beats $(0.25) Estimate, Sales $156.100M Beat $145.000M Estimate Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.25) by 184 percent. This is a 71.62 percent decrease over earnings of…
- benzinga.com Emergent BioSolutions Receives Singapore's Health Sciences Authority Approval For Expanded Indication For ACAM2000 Emergent BioSolutions Inc. (NYSE:EBS) today announced that Singapore's Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live)…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Emergent BioSolutions Signs Multi-Year, ~$50M Agreement With SAB Biotherapeutics For Development And Manufacturing Of SAB-142, SAB's Lead Program In Clinical Development For Autoimmune Type 1 Diabetes The executed agreement is valued at approximately $50 million, of which $36 million is contingent on future regulatory approval and downstream milestones.Under the terms of the agreement, Emergent…